retatrutide and perimenopause Reta Weight Loss: Phase 3 Trial Data What Patients Actually Report in 2026 Perimenopause Facts: It Starts Earlier
Description
This is promising
In Phase 3 trials, the highest dose produced 28.7% average weight loss at 68 weeks nearly double what semaglutide achieves
Tirzepatide is another weight loss injection that is also a dual agonist, meaning it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Consult your GP if you experience unexplained weight gain (particularly facial and abdominal), persistent hypertension, easy bruising, purple stretch marks, muscle weakness, or mood changes
Medicare explicitly excludes coverage for weight-loss medications (unless there are associated cardiovascular risks)
